melanoma

5 Cancer Vaccines to Watch in 2024
5 Cancer Vaccines to Watch in 2024
BioSpace
Merck
Moderna Therapeutics
melanoma
BioNTech
pancreatic cancer
OSE Immunotherapeutics
Transgene
non-small cell lung cancer
Nykode Therapeutics
cervical cancer
Flag link:
IO Biotech concludes subject enrollment in melanoma vaccine trial
IO Biotech concludes subject enrollment in melanoma vaccine trial
Clinical Trials Arena
IO Biotech
clinical trial
melanoma
vaccines
Flag link:
Cancer vaccine shows promising long-term survival data
Cancer vaccine shows promising long-term survival data
Biopharma Reporter
Ultimovacs
cancer vaccines
vaccines
melanoma
Flag link:
Bristol Myers Squibb's Opdivo reign expands with new earlier-stage melanoma nod
Bristol Myers Squibb's Opdivo reign expands with new earlier-stage melanoma nod
Fierce Pharma
Bristol Myers Squibb
Opdivo
melanoma
FDA
Flag link:
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
melanoma
colorectal cancer
non-small cell lung cancer
Flag link:
FDA capacity forces delay to Iovance's cell therapy
FDA capacity forces delay to Iovance's cell therapy
Pharmaphorum
Iovance Biotherapeutics
lifileucel
cell therapy
FDA
melanoma
Flag link:
Bristol Myers gets positive opinion from CHMP for Opdivo
Bristol Myers gets positive opinion from CHMP for Opdivo
Pharmaceutical Business Review
Bristol Myers Squibb
Opdivo
CHMP
Europe
melanoma
Flag link:
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
BioSpace
Merck
Keytruda
Eisai
Lenvima
melanoma
clinical trials
cancer
colorectal cancer
Flag link:
Moderna’s experimental cancer vaccine treats but doesn’t prevent melanoma – a biochemist explains how it works
Moderna’s experimental cancer vaccine treats but doesn’t prevent melanoma – a biochemist explains how it works
The Conversation
Moderna Therapeutics
vaccines
cancer
melanoma
Flag link:
Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial
Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial
Fierce Biotech
Merck
Moderna Therapeutics
MRNA
cancer immunotherapy
Keytruda
melanoma
Flag link:
Replimune’s melanoma success looks more than skin deep
Replimune’s melanoma success looks more than skin deep
EP Vantage
Replimune
melanoma
clinical trials
RP1
Flag link:
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Endpoints
Bristol Myers Squibb
Opdivo
melanoma
Merck
Keytruda
Flag link:
Merck and Moderna Move Forward with Personalized Cancer Vaccine
Merck and Moderna Move Forward with Personalized Cancer Vaccine
BioSpace
Merck
Moderna Therapeutics
vaccines
mRNA-4157/V940
melanoma
Flag link:
OncoSec sheds 45% of staff to fund IL-12 drug through Keytruda combo trial
OncoSec sheds 45% of staff to fund IL-12 drug through Keytruda combo trial
Fierce Biotech
OncoSec Medical
melanoma
clinical trials
Keytruda
layoffs
Tavo
Flag link:
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Fierce Pharma
Merck
Keytruda
Bristol Myers Squibb
Opdivo
melanoma
Flag link:
Sapience receives orphan designation for ST101 to treat advanced melanoma
Sapience receives orphan designation for ST101 to treat advanced melanoma
Pharmaceutical Business Review
Sapience Therapeutics
ST101
melanoma
Flag link:
What’s next for Bristol Myers' relatlimab?
What’s next for Bristol Myers' relatlimab?
EP Vantage
Bristol Myers Squibb
relatilimab
Opdivo
Opdualag
melanoma
Flag link:
Nektar Left Reassessing After Canceled Melanoma Trials
Nektar Left Reassessing After Canceled Melanoma Trials
BioSpace
Nektar
Bristol Myers Squibb
clinical trials
melanoma
bempegaldesleukin
Flag link:
Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial
Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial
Endpoints
Idera Pharmaceuticals
AbbVie
melanoma
clinical trials
tilsotolimod
Flag link:
Keytruda wins eighth FDA approval of 2021, moving into adjuvant and pediatric melanoma settings
Keytruda wins eighth FDA approval of 2021, moving into adjuvant and pediatric melanoma settings
Endpoints
Merck
Keytruda
melanoma
adolescents
Flag link:

Pages